By John Miller ZURICH (Reuters) – Signals from Swiss drugmaker Novartis that it could unload its struggling Alcon eyecare business is the latest step in dismantling former leader Dan Vasella's vision of building a European healthcare giant. Chairman Joerg Reinhardt said at the weekend that Alcon's woes have intensified soul-searching over the unit's future. “All options are open in the future,” Chairman Joerg Reinhardt said in an interview in Swiss weekly SonntagsZeitung.
Read more:
The Novartis house that Vasella built gets extreme makeover